feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Business and Economy / Granules India Launches Pharma Innovation Hubs at IIT Hyderabad

Granules India Launches Pharma Innovation Hubs at IIT Hyderabad

1 Dec, 2025

•

Summary

  • Granules India inaugurated two advanced Centres of Excellence at IIT Hyderabad.
  • One center focuses on developing cosmetic, therapeutic, and pharmaceutical peptides.
  • The other center advances polymorph research and novel drug delivery systems.
Granules India Launches Pharma Innovation Hubs at IIT Hyderabad

Granules India has significantly boosted its pharmaceutical innovation capabilities with the inauguration of two advanced Centres of Excellence at the Technology Research Park of IIT Hyderabad. These state-of-the-art facilities, established on Monday, December 1, 2025, are poised to drive significant advancements in the pharmaceutical sector.

The Ascelis Center of Excellence for Peptide Development and Characterisation, operating under Granules' CDMO arm, Ascelis Peptides, will spearhead the development of peptides for cosmetic, therapeutic, and pharmaceutical uses. This facility marks Ascelis' first development and characterisation center in India, equipped with advanced analytical tools to characterize peptide structures and processes, aiming to reduce reliance on external partners.

trending

BCA withdraws ICE shooting investigation

trending

Real Sociedad late win

trending

Morocco beats Cameroon in AFCON

trending

Unemployment rate dipped to 4.4%

trending

McIntyre wins WWE Championship

trending

Wrexham beats Nottingham Forest

trending

Mark Cuban donates to Indiana

trending

Whittington game-time call versus IU

trending

Dortmund draws with Frankfurt

Complementing this is the Granules Center of Excellence for Particle Engineering, dedicated to advancing polymorph research, material science, and novel drug delivery systems, including amorphous solid dispersions. This dedicated platform is designed to secure first-to-file opportunities, enhance formulation performance, and develop proprietary technologies for regulated markets, thereby elevating global competitiveness.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Granules India inaugurated two advanced Centres of Excellence at IIT Hyderabad: one for peptide development and another for particle engineering.
It is Granules India's first development and characterisation facility in India for cosmetic, therapeutic, and pharmaceutical peptides, collaborating with their Swiss R&D.
This center will advance polymorph research, material science, and novel drug delivery systems, aiming to create proprietary technologies for regulated markets.

Read more news on

Business and Economyside-arrow

You may also like

Flu & RSV Surge: Simple Precautions Urged

3 Jan • 30 reads

article image

India's Weight-Loss Drug Boom: Patient Willingness Drives Market

3 Jan • 61 reads

article image

New Delhi's AQI Hits 700: Your Survival Kit Revealed

15 Dec, 2025 • 100 reads

article image

Granules India Facility Aces US FDA Inspection

4 Dec, 2025 • 162 reads

article image

Peptide Trend: Youthful Looks or Risky Research?

30 Nov, 2025 • 107 reads

article image